The eukaryotic Initiating Factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia

phopshatidylserine exposure, which may be reached only during acute crisis and not in patients undergoing RCE as a preventive therapy. In conclusion, using a triple Annexin V/CD41/GPA staining that enabled us to detect and quantify both platelets-derived and erythrocytes-derived MPs in the same sample, we confirmed that the MPs from both origins are clearly increased in SCD patients. Moreover, we observed a selective reduction in the number of erythrocytes-derived MPs after RCE, while the number of platelets-derived MPs and total MPs remained unchanged. This selective reduction of erythrocytes-derived MPs could contribute to the benefit of this procedure as a prevention of stroke in SCD patients.

[1]  J. Tamburini,et al.  Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia , 2010, Clinical Cancer Research.

[2]  J. Tamburini,et al.  Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies , 2010, Leukemia.

[3]  A. Hsieh,et al.  Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in Cancer , 2010, Clinical Cancer Research.

[4]  P. Pandolfi,et al.  eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression , 2010, Proceedings of the National Academy of Sciences.

[5]  M. Bernard,et al.  Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial , 2010, Leukemia.

[6]  J. Tamburini,et al.  Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. , 2009, Blood.

[7]  Axel Benner,et al.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[8]  J. Tamburini,et al.  Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. , 2008, Blood.

[9]  J. Graff,et al.  eIF-4E expression and its role in malignancies and metastases , 2004, Oncogene.

[10]  A. Gingras,et al.  Regulation of translation initiation by FRAP/mTOR. , 2001, Genes & development.